Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward C. Jones is active.

Publication


Featured researches published by Edward C. Jones.


The American Journal of Surgical Pathology | 2005

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Jonathan I. Epstein; William C. Allsbrook; Mahul B. Amin; Lars Egevad; Sheldon Bastacky; Antonio Lòpez Beltran; Aasmund Berner; Athanase Billis; Liliane Boccon-Gibod; Liang Cheng; Francisco Civantos; Cynthia Cohen; Michael B. Cohen; Milton W. Datta; Charles J. Davis; Brett Delahunt; Warick Delprado; John N. Eble; Christopher S. Foster; Masakuni Furusato; Paul B. Gaudin; David J. Grignon; Peter A. Humphrey; Kenneth A. Iczkowski; Edward C. Jones; Scott Lucia; Peter McCue; Tipu Nazeer; Esther Oliva; Chin Chen Pan

Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging-targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.


The American Journal of Surgical Pathology | 1998

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder

Jonathan I. Epstein; Mahul B. Amin; Victor R. Reuter; F. K. Mostofi; Ferran Algaba; William C. Allsbrook; Alberto G. Ayala; Michael J. Becich; Antonio Lòpez Beltran; Lilliane Boccon-Gibód; David G. Bostwick; Christer Busch; Charles J. Davis; John N. Eble; Christopher S. Foster; Masakuni Furusato; David J. Grignon; Peter A. Humphrey; Elia A. Ishak; Sonny L. Johansson; Edward C. Jones; Leopold G. Koss; Howard S. Levin; William M. Murphy; Robert O. Petersen; Andrew A. Renshaw; Jae Y. Ro; Jeffrey R. Ross; Isabell A. Sesterhenn; John R. Srigley

In October 1997, Dr. F.K. Mostofi assembled a group of individuals interested in bladder neoplasia at a meeting in Washington DC. The participants included urologic pathologists, urologists, urologic oncologists, and basic scientists with an interest in bladder neoplasia. The purpose of this meeting was to discuss bladder terminology and make recommendations to the World Health Organization (WHO) Committee on urothelial tumors. Following this meeting, a group of the urologic pathologists who attended the Washington meeting decided to broaden the representation of the group and arranged a meeting primarily of the members of the International Society of Urologic Pathologists (ISUP) at the 1998 United States and Canadian Academy of Pathology Meeting held in Boston. Massachusetts. At this meeting. issues regarding terminology of bladder lesions, primarily neoplastic and putative preneoplastic lesions, were discussed, resulting in a consensus statement. The WHO/ ISUP consensus classification arises from this consensus conference committees recommendations to the WHO planning committee and their agreement with virtually all of the proposals presented herein. 29 The effort involved in reaching such a consensus was often considerable. Many of those involved in this process have compromised to arrive at a consensus. The aim was to develop a universally acceptable classification system for bladder neoplasia that could be used effectively by pathologists, urologists, and oncologists.


Journal of Magnetic Resonance Imaging | 2006

Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology

Piotr Kozlowski; Silvia D. Chang; Edward C. Jones; Kenneth W. Berean; Henry Chen; S. Larry Goldenberg

To determine whether the combination of diffusion‐weighted (DW) and dynamic contrast‐enhanced (DCE) MRI provides higher diagnostic sensitivity for prostate cancer than each technique alone.


The American Journal of Surgical Pathology | 1993

Inflammatory pseudotumor of the urinary bladder. A clinicopathological, immunohistochemical, ultrastructural, and flow cytometric study of 13 cases.

Edward C. Jones; Philip B. Clement; Robert H. Young

We report 13 cases of inflammatory pseudotumor of the urinary bladder in patients having no history of recent local trauma. The average age of the patients (eight females, five males) was 35.4 years (range, 19 to 60 years). Gross hematuria (nine of 13 cases) and recurrent cystitis (three of 13 cases) were the most common presentations. Cystoscopy and gross examination revealed either a polypoid intraluminal mass or a submucosal mural mass, ranging in size from 2 to 7 cm. The lesions were commonly gelatinous. Histological examination showed that the lesions consisted of spindle cells with tapering eosinophilic cytoplasm, typically widely separated in a vascular myxoid matrix with acute and chronic inflammatory cells. In four cases the lesions had more compact cellularity with areas of fibrosis and less myxoid change. The muscularis propria was involved in 10 cases, the perivesical fat in two cases. The spindle cells were immunoreactive for vimentin (10 of 10) and muscle-specific actin (10 of 10). A few cases exhibited immunoreactivity for smoothmuscle- specific actin (three of eight), cytokeratin (two of 10), desmin (two of nine), and epithelial membrane antigen (two of eight). Ultrastructural examination of four cases revealed myofibroblasts, fibroblasts, or a mixture of the two cell types. DNA content analysis by flow cytometry yielded diploid histograms (six of six). Clinical follow-up in all cases demonstrated no evidence of recurrence (mean follow-up, 25.8 months). The findings indicate that this lesion is a benign, likely inflammatory or reparative, mesenchymal lesion that can be recognized by its distinctive pathological features


Modern Pathology | 2001

Inflammatory Pseudotumor and Sarcoma of Urinary Bladder: Differential Diagnosis and Outcome in Thirty-Eight Spindle Cell Neoplasms

Kenneth A. Iczkowski; Jonathan H Shanks; Virgil Gadaleanu; Liang Cheng; Edward C. Jones; Roxann M. Neumann; Antonio G. Nascimento; David G. Bostwick

We assessed diagnostic criteria among 38 spindle cell tumors of the urinary bladder and obtained follow-up in 36 patients. Patients comprised 28 males and 10 females aged 2.5 months to 87 years. Hematuria was the commonest presenting symptom (27 patients). After review and immunohistochemical workup, 17 patients had inflammatory pseudotumor (myofibroblastic tumor), 4 postoperative spindle cell nodule, 1 leiomyoma, 13 sarcoma (7 low-grade; 6 high-grade), and 3 carcinoma. Mean age was 38 years for pseudotumor (range 15 to 74), 65 for postoperative spindle cell nodule, 51 for sarcoma, and 76 for carcinoma. Size of pseudotumor averaged 4.4 ± 0.7 cm (range 1.5 to 13.0), similar to sarcoma, 4.0 ± 0.6 cm (range 0.5 to 7.0). Similar proportions of benign tumors and sarcomas had muscularis propria invasion. The criteria that best differentiated sarcoma from inflammatory pseudotumor were presence of necrosis at the tumor-detrusor muscle interface in muscle-invasive cases, and nuclear atypia. Sarcoma also had less prominent microvasculature, less variable cellularity, consistently ≥1 mitotic figure per 10 high-power fields, and predominant acute inflammation without plasma cells. p53 protein nuclear immunostaining was moderate, unlike the rare to absent staining in pseudotumors. Because all 12 sarcomas were desmin-negative, we did not call them leiomyosarcoma; they overlapped with benign tumor in epithelial, mesenchymal, and actin immunostaining. Among 12 sarcoma patients, 2 died of tumor (at 3 months). Two of four experienced tumor recurrence after partial cystectomy (2 and 26 months). No pseudotumors recurred after transurethral resection or partial cystectomy, although one patient, 5 months after transurethral resection, had histologically identical pseudotumor that the surgeon considered residual. Another patient with pseudotumor, not a candidate for tumor ablation after transurethral resection, had continued tumor growth and he died of urosepsis. In conclusion, inflammatory pseudotumor, although overlapping with sarcoma in presentation, age range, and size, does not metastasize and remains histologically distinct from low-grade sarcoma.


Cancer Research | 2004

Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis

Peter K. Cheung; Bruce Woolcock; Hans Adomat; Margaret Sutcliffe; Terry C. Bainbridge; Edward C. Jones; Douglas Webber; Thomas Kinahan; Marianne D. Sadar; Martin Gleave; Juergen R. Vielkind

Identification of proteomic alterations associated with early stages in the development of prostate cancer may facilitate understanding of progression of this highly variable disease. Matched normal, high-grade prostatic intraepithelial neoplasia (hPIN) and prostate cancer cells of predominantly Gleason grade 3 were procured by laser capture microdissection from serial sections obtained from snap-frozen samples dissected from 22 radical prostatectomy specimens. From these cells, protein profiles were generated by surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A 24-kDa peak was observed at low or high intensity in profiles of prostate cancer cells in 19 of 27 lesions and at low intensity in 3 of 8 hPIN lesions but was not detectable in matched normal cells. SDS-PAGE analysis of prostate cancer and matched normal epithelium confirmed expression of a prostate cancer-specific 24-kDa protein. Mass spectrometry and protein data-based analysis identified the protein as the dimeric form of mature growth differentiation factor 15 (GDF15). The increased expression of mature GDF15 protein in prostate cancer cells cannot be explained on the basis of up-regulation of GDF15 mRNA because reverse transcription-PCR analysis showed similar amounts of transcript in normal, hPIN, and prostate cancer cells that were obtained by laser capture microdissection in the same set of serial sections from which the protein profiles were obtained. Our findings suggest that early prostate carcinogenesis is associated with expression of mature GDF15 protein.


Modern Pathology | 2001

Comparison of the WHO/ISUP Classification and Cytokeratin 20 Expression in Predicting the Behavior of Low-Grade Papillary Urothelial Tumors

A Alsheikh; Z Mohamedali; Edward C. Jones; J Masterson; C B Gilks

It has not been possible to identify those low-grade papillary transitional cell bladder tumors that will recur based on conventional histopathologic assessment. Both the new World Health Organization/International Society of Urologic Pathology (WHO/ISUP) classification of transitional cell papillary neoplasms and the pattern of tumor cytokeratin 20 (CK20) immunostaining have been suggested as means of improving prognostication in low-grade transitional cell tumors. Forty-nine low-grade, noninvasive papillary transitional cell tumors were identified for the period between 1984 and 1993. The recently described WHO/ISUP classification was applied, and the tumors were classified histologically as papilloma, papillary neoplasm of low malignant potential (LMP) or low-grade papillary carcinoma. After CK20 immunostaining, the expression pattern in the tumor was classified as normal (superficial) or abnormal. Of 49 tumors, 20 were classified as papillary neoplasms of LMP and five of these patients (25%) experienced a recurrence. Of 29 tumors classified as low-grade papillary carcinoma, 14 (48.2%) recurred. In 46 of 49 cases, the CK20 immunostaining could be evaluated. Sixteen tumors showed normal (superficial) pattern of CK20 expression, and four (25%) of these patients experienced a recurrence. In contrast, of 30 patients with abnormal CK20 staining of their tumors, 15 (50%) patients had one or more recurrences. In this study, papillary neoplasms of LMP (as per the WHO/ISUP classification system) had a lower recurrence rate than low-grade papillary transitional cell carcinoma. Similarly low-grade urothelial tumors showing a normal CK20 expression pattern recurred less frequently than tumors with an abnormal pattern of CK20 staining. Neither of these differences was statistically significant, and recurrences were observed in 20% of patients whose tumors were both classified as papillary neoplasms of LMP and showed normal CK20 immunostaining; thus they do not allow a change in our current management of patients with low-grade papillary urothelial tumors, with close follow-up for all patients.


The Journal of Urology | 1990

Resection Margin Status in Radical Retropubic Prostatectomy Specimens: Relationship to Type of Operation, Tumor Size, Tumor Grade and Local Tumor Extension

Edward C. Jones

Since the introduction of the nerve-sparing radical retropubic prostatectomy, there has been a steady increase in the number of prostatic cancer cases treated operatively and concern with the frequency of positive resection margins has developed. To identify factors that determine resection margin status the hospital charts of 199 radical retropubic prostatectomy patients from 1980 to 1987 were reviewed, as well as slides from 52 patients in 1987. Of the 199 patients 92 (46%) had positive resection margins; there was no difference in the frequency between the nerve-sparing and standard procedures. The 1987 slide review showed a positive resection margin frequency of 58%. The presence and extent of positive resection margins were directly related to tumor size. The positive resection margin frequency also increased with poorly differentiated carcinoma, capsular penetration and seminal vesicle involvement. Determination of these risk factors identifies patients at greatest risk for positive resection margins.


The American Journal of Surgical Pathology | 2008

Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens

Andrew Evans; Pauline Henry; Theodorus H. van der Kwast; Douglas C. Tkachuk; Kemp Watson; Gina Lockwood; Neil Fleshner; Carol C. Cheung; Eric C. Belanger; Mahul B. Amin; Liliane Boccon-Gibod; David G. Bostwick; Lars Egevad; Jonathan I. Epstein; David J. Grignon; Edward C. Jones; Rodolfo Montironi; Madeleine Moussa; Joan Sweet; Kiril Trpkov; Thomas M. Wheeler; John R. Srigley

Accurate Gleason score, pathologic stage, and surgical margin (SM) information is critical for the planning of post-radical prostatectomy management in patients with prostate cancer. Although interobserver variability for Gleason score among urologic pathologists has been well documented, such data for pathologic stage and SM assessment are limited. We report the first study to address interobserver variability in a group of expert pathologists concerning extraprostatic soft tissue (EPE) and SM interpretation for radical prostatectomy specimens. A panel of 3 urologic pathologists selected 6 groups of 10 slides designated as being positive, negative, or equivocal for either EPE or SM based on unanimous agreement. Twelve expert urologic pathologists, who were blinded to the panel diagnoses, reviewed 40× whole-slide scans and provided diagnoses for EPE and SM on each slide. On the basis of panel diagnoses, as the gold standard, specificity, sensitivity, and accuracy values were high for both EPE (87.5%, 95.0%, and 91.2%) and SM (97.5%, 83.3%, and 90.4%). Overall κ values for all 60 slides were 0.74 for SM and 0.63 for EPE. The κ values were higher for slides with definitive gold standard EPE (κ=0.81) and SM (κ=0.73) diagnoses when compared with the EPE (κ=0.29) and SM (κ=0.62) equivocal slides. This difference was markedly pronounced for EPE. Urologic pathologists show good to excellent agreement when evaluating EPE and SM. Interobserver variability for EPE and SM interpretation was principally related to the lack of a clearly definable prostatic capsule and crush/thermal artifact along the edge of the gland, respectively.


Cancer | 1990

Dna content in prostatic adenocarcinoma a flow cytometry study of the predictive value of aneuploidy for tumor volume percentage gleason grade 4 and 5 and lymph node metastases

Edward C. Jones; John E. McNeal; N. Bruchovsky; G. de Jong

DNA content of prostatic adenocarcinoma was determined by flow cytometry on formalin‐fixed, paraffin‐embedded tissue from 57 radical prostatectomies. This was done to define the relationship of aneuploidy to prostatic adenocarcinoma grade, volume, and pathologic stage and to examine its utility in candidates for surgical treatment. Aneuploidy was found in 26 (46%) cases. With one exception, all of the aneuploid cases were found in tumors larger than 4 cc. The percentage of aneuploid cases increased with advancing pathologic stage, and it was highest in those cases with lymph node metastases. This percentage was also higher among more poorly differentiated tumors. However, diploid tumors were also found among these groups, and the relationship between aneuploidy versus pathologic stage and grade did not achieve statistical significance. Except for a 91% specificity for tumor volume greater than 4 cc, the sensitivity and specificity of DNA content analysis to predict these groups was low (50% to 72%). It is concluded that aneuploidy is a later event linked to tumor progression, but it is not a requirement for progression to occur. The overlap in aneuploid and diploid tumor behavior precludes the use of DNA content analysis as an independent predictor to direct preoperative treatment of prostatic carcinoma.

Collaboration


Dive into the Edward C. Jones's collaboration.

Top Co-Authors

Avatar

S. Larry Goldenberg

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Piotr Kozlowski

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Silvia D. Chang

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Ladan Fazli

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Septimiu E. Salcudean

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Guy Nir

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Martin Gleave

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Mehdi Moradi

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter C. Black

University of British Columbia

View shared research outputs
Researchain Logo
Decentralizing Knowledge